SOLENO THERAPEUTICS INC (SLNO) Stock Profile — Insider Trades & Financials

Revenue$91.7M

Net Income$43.4M

EPS$0.39

Market Cap$2.7B

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Anish Bhatnagar

CEO & Executive Director

Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.

Founded: 1999
Employees: 182
Headquarters: Redwood City, California, United States
Website

⚡

Core Efficiency

ROE?

9.63%

ROA?

7.69%

D/E Ratio?

0.25

Op. Margin?

43.15%

📊

Profitability Ratios

Net Margin?

47.27%

Loading company sections...

SOLENO THERAPEUTICS INC

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness